GIVAUDAN PLANNING FIVE (NDAs) FOR PARSOL 1789 SUNSCREEN
GIVAUDAN PLANNING FIVE (NDAs) FOR PARSOL 1789 SUNSCREEN in November, according to the ingredient supplier. The five NDAs are for finished OTC sunscreen formulations containing Givaudan's patented UVA-absorbing ingredient Parasol 1789 (butyl methoxydibenzoylmethane). Two of the formulations would have sun protection factors of 10. They also contain Givaudan's Parsol MCX (octyl methoxycinnamate), a Category I UVB-ray blocking ingredient. The five formulas contain Parsol 1789 at a concentration of 3%, which is the same strength used in Herbert Labs' Photoplex, the first Parsol 1789 product to receive an approved NDA ("The Pink Sheet" Oct. 10, T&G-5). Givaudan, a subsidiary of Roche, began negotiations with FDA last year to design and expedited process for other marketers to seek approval. The company would like to develop a method of approval in order to alleviate the need for FDA to review large numbers of similar NDAs for products formulated with Parsol 1789 and other active sunscreen ingredients, or for inert ingredient modifications. The Parsol situation provides a good example of the regulatory logjam of OTC applications that FDA will face in the post-monograph period. As the process now exists, Givaudan will hold NDAs, and product marketers will be restricted to licensing those formulations. To introduce new formulations, marketers would be required to file subsequent NDAs or convince FDA to accept some form of ANDA petition process.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth